Bolt Biotherapeutics, Inc. BOLT
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Bolt Biotherapeutics, Inc. (BOLT) is a healthcare company listed in the US with a market value of about $16M. In the twelve months to September 30, 2026 it had revenue of $3M and net income of -$26M, a net margin of -1034.4%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 102% a year, a 5-year average ROIC of -54%.
About Bolt Biotherapeutics
Bolt Biotherapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $231000 in 2020 to $8M in 2025, growth of about 101.6% a year. It was profitable in 0 of the last 6 years in our data. It spends 371% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $3M | $8M | $8M | $8M | $6M | $1M | $231000 |
| Net income | -$26M | -$33M | -$63M | -$69M | -$88M | -$99M | -$61M |
| Free cash flow | -$25M | -$40M | -$61M | -$70M | -$78M | -$59M | -$51M |
| EPS (diluted) | $-14.03 | $-17.85 | $-33.06 | $-36.60 | $-47.20 | $-59.40 | $-577.79 |
| Net margin | -1034.4% | -433.7% | -820.8% | -878.6% | -1537.8% | -7824.7% | -26289.2% |
| ROIC | — | -73.0% | -88.6% | -45.3% | -36.8% | -26.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Bolt Biotherapeutics pay a dividend?
Not currently.
Is Bolt Biotherapeutics a good stock to buy?
We do not give buy or sell advice. Bolt Biotherapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.